keyword
https://read.qxmd.com/read/38699182/a-comprehensive-dataset-on-biomechanics-and-motor-control-during-human-walking-with-discrete-mechanical-perturbations
#21
JOURNAL ARTICLE
Dana L Lorenz, Antonie J van den Bogert
BACKGROUND: Humans have a remarkable capability to maintain balance while walking. There is, however, a lack of publicly available research data on reactive responses to destabilizing perturbations during gait. METHODS: Here, we share a comprehensive dataset collected from 10 participants who experienced random perturbations while walking on an instrumented treadmill. Each participant performed six 5-min walking trials at a rate of 1.2 m/s, during which rapid belt speed perturbations could occur during the participant's stance phase...
2024: PeerJ
https://read.qxmd.com/read/38698650/effect-of-semaglutide-2-4%C3%A2-mg-on-physical-functioning-and-weight-and-health-related-quality-of-life-in-adults-with-overweight-or-obesity-patient-reported-outcomes-from-the-step-1-4-trials
#22
JOURNAL ARTICLE
Domenica Rubino, Jakob B Bjorner, Naveen Rathor, Arya M Sharma, Lisa von Huth Smith, Sean Wharton, Thomas Wadden, Niels Zeuthen, Ronette L Kolotkin
AIMS: To summarize the effects of semaglutide 2.4 mg on weight-related quality of life (WRQOL) and health-related quality of life (HRQOL), focusing on the confirmatory secondary endpoint of physical functioning. MATERIALS AND METHODS: The STEP 1-4 Phase 3a, 68-week, double-blind, randomized controlled trials assessed the efficacy and safety of semaglutide 2.4 mg versus placebo in individuals with overweight/obesity. WRQOL and HRQOL were assessed by change from baseline to Week 68 in two different but complementary measures, the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT; STEP 1 and 2) and the SF-36v2 Health Survey Acute (SF-36v2; STEP 1-4)...
May 2, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38698434/correction-methodology-of-the-sorento-clinical-trial-a-prospective-randomised-active-controlled-phase-3-trial-assessing-the-efficacy-and-safety-of-high-exposure-octreotide-subcutaneous-depot-cam2029-in-patients-with-gep-net
#23
Simron Singh, Diego Ferone, Jaume Capdevila, Jennifer Ang Chan, Wouter W de Herder, Daniel Halperin, Josh Mailman, Lisa Hellström, Hanna Liedman, Agneta Svedberg, Fredrik Tiberg
No abstract text is available yet for this article.
May 2, 2024: Trials
https://read.qxmd.com/read/38698285/pharmacokinetics-pharmacodynamics-safety-and-tolerability-of-oral-al01211-in-healthy-chinese-volunteers
#24
JOURNAL ARTICLE
Lei Dong, Jianxing Xiang, Michael Babcock, Yuanzhi Cheng, Yan Wang, Yuqiao Shen, Li Li, Liping Tan, Marvin Garovoy, Wei Hu, Jianhong Zheng
BACKGROUND AND OBJECTIVE: Aberrant accumulation of glycosphingolipids (GSLs) in the lysosome leads to GSL storage diseases. Glucosylceramide synthase inhibitors (GCSi) have the potential to treat several GSL storage diseases by reducing the synthesis of the disease-causing GSLs. AL01211 is a potent oral GCSi under investigation for Type 1 Gaucher disease and Fabry disease. Here, we evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of AL01211 in healthy Chinese volunteers...
May 2, 2024: Clinical Drug Investigation
https://read.qxmd.com/read/38698274/multi-nutrients-and-periodontal-disease-a-new-adjunct-to-improving-treatment-outcomes-a-randomised-placebo-control-clinical-trial
#25
JOURNAL ARTICLE
Ryan McSorley
DESIGN: This study by Laky et al. is a single-centre, double-blinded randomised placebo-controlled clinical trial, examining the effects of micronutrient supplementation in combination with non-surgical hygiene phase therapy (nsHPT) for Stage III and IV periodontal disease. The study was carried out at the Medical University of Vienna (Austria), School of Dentistry. The patients enrolled in the study were randomised to receive a commercially available multi-nutrient supplement (containing: vitamin C, vitamin E, zinc, selenium, alpha-lipoic-acid, cranberry extract, grapeseed extract, and coenzyme Q10) or a cellulose placebo to take for 2 months, alongside a course of non-surgical hygiene phase therapy...
May 2, 2024: Evidence-based Dentistry
https://read.qxmd.com/read/38698080/treatment-of-newly-diagnosed-moderate-or-severe-chronic-graft-versus-host-disease-with-prednisone-and-everolimus-predever-first-a-prospective-multicenter-phase-iia-study
#26
JOURNAL ARTICLE
Francis Ayuk, Eva-Maria Wagner-Drouet, Daniel Wolff, Natascha von Huenerbein, Ute-Marie von Pein, Evgeny Klyuchnikov, Stephanie von Harsdorf, Christian Koenecke, Herbert Sayer, Nicolaus Kröger
Although most patients with chronic graft-versus-host disease (cGVHD) show initial response to first-line therapy, long-term clinically meaningful success of first-line treatment remains rare. In a prospective multicentre phase II trial in 6 German centers, patients with newly diagnosed moderate or severe cGVHD received prednisone and everolimus for 12 months followed by a 1-year follow-up period. Primary endpoint was treatment success (TS) at 6 months defined as patient being alive, achieving PR or CR of cGVHD, having no relapse of underlying disease and requiring no secondary treatment for cGVHD...
May 2, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38697873/zuranolone-a-narrative-review-of-a-new-oral-treatment-for-postpartum-depression
#27
REVIEW
Emily M Hitt
PURPOSE: Postpartum depression is a prevalent and overlooked mental disorder. Pathophysiology is thought to originate from a combination of biological and social factors, including hormones, and genetics. The consequences of untreated postpartum depression can be severe and negatively impact maternal and infant health. Zuranolone was approved as an oral agent in August 2023 for the treatment of postpartum depression in adults. The purpose of this article is evaluating the clinical aspects of zuranolone, including safety and efficacy pertaining to the drug and the clinical data that led to its approval...
May 1, 2024: Clinical Therapeutics
https://read.qxmd.com/read/38697511/the-efficacy-and-safety-of-a-fixed-dose-combination-of-apocynin-and-paeonol-appa-in-symptomatic-knee-oa-a-double-blind-randomized-placebo-controlled-clinical-trial
#28
JOURNAL ARTICLE
Asger Reinstrup Bihlet, Inger Byrjalsen, Jeppe Ragnar Andersen, Alan Reynolds, Nicholas Larkins, Peter Alexandersen, Helene Rovsing, Robert Moots, Philip G Conaghan
OBJECTIVE: Apocynin (AP) and paeonol (PA) are low molecular weight phenolic compounds with a broad array of anti-inflammatory and immunoregulatory effects. This study assessed of a fixed-dose combination of APPA in people with symptomatic knee osteoarthritis (OA). METHODS: A multi-center, randomized, placebo-controlled, double-blind phase 2a trial enrolled participants with radiographic knee OA (Kellgren-Lawrence, KL, grades 2-3) and pain ≥40/100 on WOMAC pain subscale, and evaluated the efficacy and safety of oral APPA over a 28-day period...
April 30, 2024: Osteoarthritis and Cartilage
https://read.qxmd.com/read/38697184/setmelanotide-for-the-treatment-of-acquired-hypothalamic-obesity-a-phase-2-open-label-multicentre-trial
#29
JOURNAL ARTICLE
Christian L Roth, Cecilia Scimia, Ashley H Shoemaker, Michael Gottschalk, Jennifer Miller, Guojun Yuan, Sonali Malhotra, M Jennifer Abuzzahab
BACKGROUND: Hypothalamic obesity resulting from hypothalamic damage might affect melanocortin signalling. We investigated the melanocortin-4 receptor agonist setmelanotide for treatment of hypothalamic obesity. METHODS: This phase 2, open-label, multicentre trial was done in five centres in the USA. Eligible patients were aged between 6 and 40 years with obesity and history of hypothalamic injury or diagnosis of a non-malignant tumour affecting the hypothalamus that was treated with surgery, chemotherapy, or radiation...
April 29, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38697170/a-measles-and-rubella-vaccine-microneedle-patch-in-the-gambia-a-phase-1-2-double-blind-double-dummy-randomised-active-controlled-age-de-escalation-trial
#30
JOURNAL ARTICLE
Ikechukwu Adigweme, Mohammed Yisa, Michael Ooko, Edem Akpalu, Andrew Bruce, Simon Donkor, Lamin B Jarju, Baba Danso, Anthony Mendy, David Jeffries, Anne Segonds-Pichon, Abdoulie Njie, Stephen Crooke, Elina El-Badry, Hilary Johnstone, Michael Royals, James L Goodson, Mark R Prausnitz, Devin V McAllister, Paul A Rota, Sebastien Henry, Ed Clarke
BACKGROUND: Microneedle patches (MNPs) have been ranked as the highest global priority innovation for overcoming immunisation barriers in low-income and middle-income countries. This trial aimed to provide the first data on the tolerability, safety, and immunogenicity of a measles and rubella vaccine (MRV)-MNP in children. METHODS: This single-centre, phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial was conducted in The Gambia...
April 29, 2024: Lancet
https://read.qxmd.com/read/38697155/trastuzumab-deruxtecan-versus-treatment-of-physician-s-choice-in-patients-with-her2-positive-metastatic-breast-cancer-destiny-breast02-patient-reported-outcomes-from-a-randomised-open-label-multicentre-phase-3-trial
#31
RANDOMIZED CONTROLLED TRIAL
Tanja Fehm, Francesco Cottone, Kyle Dunton, Fabrice André, Ian Krop, Yeon Hee Park, Michelino De Laurentiis, Yasuo Miyoshi, Anne Armstrong, Manuel Ruiz Borrego, Rinat Yerushalmi, Francois P Duhoux, Toshimi Takano, Wenjing Lu, Anton Egorov, Sung-Bae Kim
BACKGROUND: In DESTINY-Breast02, patients with HER2-positive unresectable or metastatic breast cancer who received trastuzumab deruxtecan demonstrated superior progression-free and overall survival compared with those receiving treatment of physician's choice. We present the patient-reported outcomes (PROs) and hospitalisation data. METHODS: In this randomised, open-label, phase 3 trial conducted at 227 clinical sites globally, enrolled patients had to be aged 18 years or older with HER2-positive unresectable or metastatic breast cancer that had progressed on trastuzumab emtansine and had an Eastern Cooperative Oncology Group performance status of 0 or 1...
May 2024: Lancet Oncology
https://read.qxmd.com/read/38696902/intratumoral-therapies-in-head-and-neck-squamous-cell-carcinoma-a-systematic-review-and-future-perspectives
#32
REVIEW
Pablo Jiménez-Labaig, Antonio Rullan, Irene Braña, Alberto Hernando-Calvo, Victor Moreno, Bernard Doger, George Bitar, Derfel Ap Dafydd, Alan Melcher, Kevin J Harrington
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) presents an ideal scenario for intratumoral therapies (IT), due to its local recurrence pattern and frequent superficial extension. IT therapies aim to effect tumor regression by directly injecting antineoplastic agents into lesions. However, there is a lack of updated evidence regarding IT therapies in HNSCC. PATIENTS AND METHODS: A systematic literature search (CRD42023462291) was conducted using WebOfScience, ClinicalTrials...
April 27, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38696862/-a-randomized-study-of-subconjonctival-bevacizumab-avastin%C3%A2-injection-for-corneal-neovascularization
#33
JOURNAL ARTICLE
M Rocher, Y Benayoun, S Quilbe, S Laribi, P Fournie, N Leveziel, M-C Trone, T Bourcier, P-Y Robert
PURPOSE: The goal of this phase III, comparative, multicentric, randomized, double-blinded clinical trial was to investigate the superiority of subconjunctival bevacizumab injections versus placebo in the treatment of corneal neovascularization. PATIENTS AND METHODS: We included 38 eyes (38 patients) with corneal neovascularization. Twenty patients received bevacizumab and 18 placebos. Patients received 3 monthly injections of either 5mg (0.2mL) bevacizumab or placebo...
April 4, 2024: Journal Français D'ophtalmologie
https://read.qxmd.com/read/38696775/regulatory-issues-in-electronic-health-records-for-adolescent-hiv-research-strategies-and-lessons-learned
#34
JOURNAL ARTICLE
Sara Shaw Green, Sung-Jae Lee, Samantha Chahin, Meardith Pooler-Burgess, Monique Green-Jones, Sitaji Gurung, Angulique Y Outlaw, Sylvie Naar
BACKGROUND: Electronic health records (EHRs) are a cost-effective approach to provide the necessary foundations for clinical trial research. The ability to use EHRs in real-world clinical settings allows for pragmatic approaches to intervention studies with the emerging adult HIV population within these settings; however, the regulatory components related to the use of EHR data in multisite clinical trials poses unique challenges that researchers may find themselves unprepared to address, which may result in delays in study implementation and adversely impact study timelines, and risk noncompliance with established guidance...
May 2, 2024: JMIR Formative Research
https://read.qxmd.com/read/38696203/smoking-cessation-after-initial-treatment-failure-with-varenicline-or-nicotine-replacement-a-randomized-clinical-trial
#35
JOURNAL ARTICLE
Paul M Cinciripini, Charles E Green, Sanjay Shete, Jennifer A Minnix, Jason D Robinson, Yong Cui, Seokhun Kim, George Kypriotakis, Diane Beneventi, Janice A Blalock, Francesco Versace, Maher Karam-Hage
IMPORTANCE: Most people who smoke do not quit on their initial attempt. OBJECTIVE: To determine the best subsequent strategy for nonabstinence following initial treatment with varenicline or combined nicotine replacement therapy (CNRT). DESIGN, SETTING, AND PARTICIPANTS: Using a double-blind, placebo-controlled, sequential multiple assignment randomized trial, 490 volunteers were randomized to receive 6 weeks of varenicline or CNRT. After 6 weeks, nonabstainers were rerandomized to continue, switch, or increase medication dosage for 6 additional weeks...
May 2, 2024: JAMA
https://read.qxmd.com/read/38696172/efficacy-of-dequalinium-chloride-vs-metronidazole-for-the-treatment-of-bacterial-vaginosis-a-randomized-clinical-trial
#36
RANDOMIZED CONTROLLED TRIAL
Grzegorz Raba, Anton Durkech, Tomáš Malík, Doerthe Bassfeld, Philipp Grob, Anahí Hurtado-Chong
IMPORTANCE: Bacterial vaginosis (BV) is a common cause of vaginal infection. First-line treatments of BV are metronidazole and clindamycin. Due to the increase in antibiotic resistance, effective nonantibiotic treatments for BV are needed. OBJECTIVE: To examine whether dequalinium chloride, a broad-spectrum antiseptic, is noninferior to oral metronidazole for the treatment of BV. DESIGN, SETTING, AND PARTICIPANTS: This phase 4, multicenter, triple-blind, double-dummy, parallel, noninferiority randomized clinical trial was conducted from July 29, 2021, to August 25, 2022, with a 1-month follow-up...
May 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38696122/improvement-in-clinical-features-of-hypercortisolism-during-osilodrostat-treatment-findings-from-the-phase-iii-linc-3-trial-in%C3%A2-cushing-s-disease
#37
JOURNAL ARTICLE
R Pivonello, M Fleseriu, J Newell-Price, A Shimatsu, R A Feelders, P Kadioglu, A Tabarin, T C Brue, E B Geer, A Piacentini, A M Pedroncelli, B M K Biller
PURPOSE: Cushing's disease is associated with substantial morbidity and impaired quality of life (QoL) resulting from excess cortisol exposure. The current study explored improvements in clinical signs and additional specific manifestations of hypercortisolism during osilodrostat (potent oral 11β-hydroxylase inhibitor) therapy by degree of control of mean urinary free cortisol (mUFC). METHODS: LINC 3 (NCT02180217) was a prospective, open-label, 48-week study of osilodrostat (starting dose: 2 mg bid; maximum: 30 mg bid) that enrolled 137 adults with Cushing's disease and mUFC > 1...
May 2, 2024: Journal of Endocrinological Investigation
https://read.qxmd.com/read/38696027/upadacitinib-rapidly-improves-patient-reported-outcomes-in-atopic-dermatitis-16-week-results-from-phase%C3%A2-3-clinical-trials-measure-up%C3%A2-1-and-2
#38
JOURNAL ARTICLE
Eric L Simpson, Vimal H Prajapati, Yael A Leshem, Raj Chovatiya, Marjolein S de Bruin-Weller, Sonja Ständer, Andrew E Pink, Brian M Calimlim, Wan-Ju Lee, Henrique Teixeira, Barry Ladizinski, Xiaofei Hu, Yang Yang, Yingyi Liu, Meng Liu, Ayman Grada, Andrew M Platt, Jonathan I Silverberg
INTRODUCTION: Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus kinase inhibitor) monotherapy on patient-reported outcomes (PROs) among adults and adolescents with moderate-to-severe AD over 16 weeks. METHODS: This integrated analysis of the double-blind, placebo-controlled periods of phase 3 monotherapy clinical trials Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422) assessed itch (Worst Pruritus Numerical Rating Scale [WP-NRS] and SCORing Atopic Dermatitis [SCORAD]), skin pain and symptom severity (AD Symptom Scale), symptom frequency (Patient-Oriented Eczema Measure), sleep (AD Impact Scale [ADerm-IS] and SCORAD), daily activities and emotional state (ADerm-IS), QoL (Dermatology Life Quality Index [DLQI] and Children's DLQI), mental health (Hospital Anxiety and Depression Scale), and patient impressions (Patient Global Impression of Severity, Patient Global Impression of Change, and Patient Global Impression of Treatment)...
May 2, 2024: Dermatology and Therapy
https://read.qxmd.com/read/38695604/final-outcomes-analysis-of-the-cell-product-sqz-pbmc-hpv-phase-1-trial-in-incurable-hpv16-solid-tumors-shows-improved-overall-survival-in-patients-with-increased-cd8-t-cell-tumor-infiltration
#39
JOURNAL ARTICLE
Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S Gordon, Kerry J Rodabaugh, Neesha Dhani, Prakash Neupane, Matthew Taylor, E Amanda Duvall, Julia Jennings, Nathan R Miselis, Scott Loughhead, Marshelle S Warren, Howard Bernstein, Jens P Klussmann, Joaquina Baranda, Antonio Jimeno
Cancer vaccines strive to induce robust, antigen-targeted, T-cell-mediated immune responses but have struggled to produce meaningful regression in solid tumors. An autologous cell vaccine, SQZ-PBMC-HPV, was developed by SQZ Biotechnologies using microfluidic squeezing technology to load PBMCs with HPV16 E6 and E7 antigens in HLA-A*02+ patients. The SQZ-PBMC-HPV-101 Phase 1 trial (NCT04084951) enrolled patients with incurable HPV16+ cancers. Here, we present a post hoc analysis of the relationship between Posttreatment CD8+ T cell infiltration and patient outcomes...
May 2, 2024: Molecular Carcinogenesis
https://read.qxmd.com/read/38695588/experiences-of-participation-in-a-study-investigating-feasibility-of-the-implantable-doppler-probe-in-kidney-transplantation-an-embedded-qualitative-study
#40
JOURNAL ARTICLE
Muhammad Shahzar Malik, Kris Houlberg, Jacob A Akoh
OBJECTIVES: Kidney transplant survival can be improved with better graft surveillance postoperatively. In the quest to explore new technologies, we explored the feasibility of an implantable Doppler probe as a blood flow monitoring device in kidney transplant patients. This qualitative study was embeddedin a feasibility trial and aimed to test the device's clinical acceptability and obtain suggestions for the development of the intervention. Objectives included exploring the experiences of feasibility study participants and identifying barriers to the implementation of implantable Doppler probes in clinical practice...
March 2024: Experimental and Clinical Transplantation
keyword
keyword
48709
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.